Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Join Us
    • Values & Culture
    • Perks & Benefits
    • Explore Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Cash Flow
  • Stock Data
    • TSX: APS
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

OHSU and Aptose Present CG’806 Preclinical Data Demonstrating Potent Activity Against Patient Samples at AACR Hematologic Malignancies Meeting

May 08, 2017 8:00am EDT

Aptose Biosciences to Participate at the Bloom Burton & Co. Healthcare Investor Conference 2017

Apr 25, 2017 8:30am EDT

Aptose To Release First Quarter Ended March 31, 2017 Financial Results and Hold Conference Call on May 11, 2017

Apr 24, 2017 8:30am EDT

Aptose Biosciences to Present CG’806 Data at AACR Hematologic Malignancies Meeting

Apr 19, 2017 8:30am EDT

Aptose Reports Fourth Quarter and Year End 2016 Results

Mar 28, 2017 5:03pm EDT

Aptose Announces Planned Departure of Chief Business Officer

Mar 27, 2017 8:00am EDT

Aptose to Participate in Upcoming Investor Conferences

Mar 02, 2017 7:00am EST

Aptose Biosciences to Present at Canaccord Genuity Rare Disease Biopharma 1x1 Day

Feb 02, 2017 7:00am EST

Aptose Prioritizes Development of CG’806 First-in Class FLT3/BTK Inhibitor

Jan 23, 2017 7:00am EST

Aptose Biosciences to Present at Biotech Showcase 2017 Conference

Jan 05, 2017 8:00am EST
RSS
  • Prev
    • 1...
    • 21
    • 22
    • 23
    • 24
    • 25
    • 26
    • 27
    • 28
    • 29
    • 30
    • ...32
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    © 2025 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences